糖皮质激素增强FLT3抑制剂对FLT3突变急性髓系白血病的抗白血病活性
研究利用RNA测序和药物筛选发现,选择性FLT3抑制剂quizartinib处理FLT3内部串联重复AML细胞后,药物耐受持续细胞(DTPs)中炎症基因上调,从而对抗炎糖皮质激素(GCs)敏感。FLT3抑制剂与GCs联合通过GC受体依赖性地上调促凋亡蛋白BIM并促进抗凋亡蛋白MCL-1的蛋白酶体降解,增强FLT3突变而非野生型细胞的死亡,并在原代AML患者样本和异种移植小鼠模型中得到验证。研究表明FLT3抑制剂与GCs联合有潜力清除DTPs,从而预防FLT3突变AML的微小残留病、突变耐药和复发。
要点
- quizartinib处理FLT3-ITD AML细胞后,DTPs中炎症基因上调,对糖皮质激素敏感。
- FLT3抑制剂联合GCs通过GC受体上调BIM并降解MCL-1,增强FLT3突变细胞死亡。
- 联合方案在原代AML样本和异种移植小鼠模型中验证,有潜力清除DTPs。
核心结论
- FLT3抑制剂与糖皮质激素联合有潜力清除DTPs,从而预防FLT3突变AML的微小残留病、突变耐药和复发。
研究设计与样本
- 使用RNA测序和药物筛选,在FLT3内部串联重复AML细胞中研究quizartinib处理后的DTPs。
- 利用原代AML患者样本和异种移植小鼠模型验证联合方案的抗白血病活性。
主要发现
- quizartinib处理FLT3内部串联重复AML细胞后,DTPs中炎症基因上调,从而对糖皮质激素敏感。
- FLT3抑制剂与GCs联合通过GC受体依赖性地上调促凋亡蛋白BIM并促进抗凋亡蛋白MCL-1的蛋白酶体降解,增强FLT3突变而非野生型细胞的死亡。
- quizartinib与地塞米松联合增强的抗白血病活性在原代AML患者样本和异种移植小鼠模型中得到验证。
临床怎么用
- 作者认为FLT3抑制剂与GCs联合有潜力清除DTPs,从而预防FLT3突变AML的微小残留病、突变耐药和复发。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistance arises and the initial response to drug treatment that promotes cell survival is unknown. Recent studies show that a transiently maintained subpopulation of drug-sensitive cells, so-called drug-tolerant "persisters" (DTPs), can survive cytotoxic drug exposure despite lacking resistance-conferring mutations. Using RNA sequencing and drug screening, we find that treatment of FLT3 internal tandem duplication AML cells with quizartinib, a selective FLT3 inhibitor, upregulates inflammatory genes in DTPs and thereby confers susceptibility to anti-inflammatory glucocorticoids (GCs). Mechanistically, the combination of FLT3 inhibitors and GCs enhances cell death of FLT3 mutant, but not wild-type, cells through GC-receptor-dependent upregulation of the proapoptotic protein BIM and proteasomal degradation of the antiapoptotic protein MCL-1. Moreover, the enhanced antileukemic activity by quizartinib and dexamethasone combination has been validated using primary AML patient samples and xenograft mouse models. Collectively, our study indicates that the combination of FLT3 inhibitors and GCs has the potential to eliminate DTPs and therefore prevent minimal residual disease, mutational drug resistance, and relapse in FLT3-mutant AML.
引用
- Gebru MT, Atkinson JM, Young MM, et al. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood. 2020. PMID: 32396937. doi:10.1182/blood.2019003124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。